Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 vs Ipamorelin for GH Research UK 2026

CJC-1295 vs Ipamorelin for GH Research UK 2026 CJC-1295 and Ipamorelin are supplied for research and laboratory use only. Neither is licensed for human GH therapy in the UK. All preclinical findings derive from peer-reviewed animal models. Any in vivo work in

By Recovery & Performance Peptides Editorial Team

CJC-1295 vs Ipamorelin for GH Research UK 2026

CJC-1295 and Ipamorelin are supplied for research and laboratory use only. Neither is licensed for human GH therapy in the UK. All preclinical findings derive from peer-reviewed animal models. Any in vivo work in the UK requires Home Office ASPA licensing.

Two Pharmacologically Distinct GH Secretagogues

CJC-1295 and Ipamorelin are both growth hormone secretagogues but operate through entirely different receptor systems with distinct pharmacological characteristics, tissue distribution, selectivity profiles, and downstream biology. Understanding this mechanistic divergence is essential for GH axis research design — the two compounds are not interchangeable, and their combination produces synergistic GH output through additive pituitary stimulation from two independent receptor populations.

CJC-1295 is a synthetic analogue of GHRH (growth hormone-releasing hormone), the hypothalamic neuropeptide that drives pulsatile GH secretion from anterior pituitary somatotrophs through GHRHR (growth hormone-releasing hormone receptor, a Gαs-coupled GPCR). CJC-1295 without DAC (drug affinity complex) is a non-acylated 30-amino acid analogue with plasma half-life of 6-8h; CJC-1295 with DAC incorporates a maleimido-propionyl-PEG2-biotin complex that binds covalently to albumin Cys34, extending half-life to approximately 6-8 days.

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂, ~711Da) is a synthetic pentapeptide GHS-R1a (growth hormone secretagogue receptor 1a, also GHR1a) agonist that activates GH release through a different pituitary receptor (Gαq-coupled) that also drives hypothalamic GHRH neurone firing — a dual pituitary+hypothalamic mechanism. GHS-R1a is structurally and pharmacologically distinct from GHRHR, with a different intracellular signalling cascade (PLC-IP3-Ca²⁺ vs cAMP-PKA).

🔗 Related Reading: For a comprehensive overview of Ipamorelin’s GHS-R1a pharmacology and research applications, see our Ipamorelin Pillar Guide.

Receptor Pharmacology: GHRHR vs GHS-R1a

GHRHR (CJC-1295 target): Gαs-coupled, expressed exclusively in anterior pituitary somatotrophs and hypothalamic SRIF neurones. Upon GHRH/CJC-1295 binding: Gαs → adenylyl cyclase → cAMP↑ → PKA → CREB phosphorylation → GH gene transcription + immediate secretory vesicle exocytosis. EC₅₀ of CJC-1295 non-DAC at GHRHR ~0.5nM (Ki by displacement radioligand binding). Downstream: GH → liver IGF-1 (the primary anabolic mediator) → STAT5b-mediated gene transcription in muscle, bone, fat, liver. GHRHR is pituitary-restricted — no significant extra-pituitary GHRHR-mediated pharmacology.

GHS-R1a (Ipamorelin target): Gαq-coupled, expressed in anterior pituitary somatotrophs AND hypothalamic arcuate GHRH neurones, heart (GHS-R1a cardiac actions), hippocampus (GHS-R1a-ghrelin cognitive effects), and multiple peripheral tissues. Upon ghrelin/Ipamorelin binding: Gαq → PLC → IP3 → ER Ca²⁺ release → calmodulin → somatotroph depolarisation and GH exocytosis. At the hypothalamic GHRH neurone: GHS-R1a activation increases GHRH release → additional pituitary GHRHR stimulation (central amplification). Ki of Ipamorelin at GHS-R1a ~1.0-1.5nM (selective: minimal activity at GHRHR, GnRH-R, motilin-R, GHS-R1b).

The critical selectivity difference: Ipamorelin is among the cleanest GHS-R1a agonists in the research portfolio — it does not significantly activate cortisol (ACTH) or prolactin pathways (unlike GHRP-2 and GHRP-6 which produce ACTH +1.8-3.0-fold and prolactin +1.4-1.8-fold through shared GHRP receptor pharmacology). CJC-1295 does not activate GHS-R1a and produces negligible cortisol/prolactin stimulation. Both are therefore the preferred GH research tools when selectivity for the GH axis is required without neuroendocrine side-effect confounds.

GH Pulse Kinetics: The Critical Pharmacokinetic Distinction

CJC-1295 non-DAC (1µg/kg i.v. bolus in SD rats) produces a GH peak of 38-44ng/mL at 15 min, declining to near-baseline by 120 min — kinetics driven by the peptide’s 6-8h plasma half-life but with GH secretion kinetics determined by somatotroph reserve and SRIF (somatostatin) inhibitory gating. Repeated dosing at 30-min intervals produces diminishing GH responses (SRIF rebound), confirming that the somatotroph pool requires refractory period between GHRH stimulations.

CJC-1295 with DAC (0.1mg/kg s.c. single dose) produces a sustained low-level GH elevation: GH baseline 2.4±0.4ng/mL (pre-dose) rising to 5.8±0.8ng/mL at 6h, maintained at 4.2-5.6ng/mL through 96h, returning to baseline by 120-144h. This sustained GH profile produces continuous IGF-1 elevation (IGF-1 42±6ng/mL pre-dose → 86±10ng/mL at 24h, maintained 78-92ng/mL through 96h) — mechanistically representing a plateau IGF-1 effect rather than pulsatile. GHRHR antagonist [D-Arg2,Lys26]-GHRH blocks 88-92% of the CJC-1295-DAC GH elevation (confirms GHRHR dependency).

Ipamorelin 200µg/kg i.p. produces GH peak of 34-38ng/mL at 15 min with return to baseline by 90-120 min. [D-Lys³]-GHRP-6 (GHS-R1a antagonist, 10mg/kg i.p.) blocks 82-86% of the GH response. ACTH at 30 min post-Ipamorelin: 42±8pg/mL vs vehicle 38±6pg/mL (NS — confirming cortisol-neutral profile). Prolactin: NS change (contrast with GHRP-6 which produces prolactin +1.6-1.8-fold). Desensitisation with repeated Ipamorelin (every 30 min × 5 doses): GH peak at dose 5 is 78±6% of dose 1 (−22% desensitisation) — less than GHRP-2 (−28-36% with equivalent pulsatile protocol) reflecting Ipamorelin’s moderate GHS-R1a internalisation kinetics.

Combination Synergy: GHRHR × GHS-R1a

The combination of CJC-1295 + Ipamorelin produces supra-additive GH secretion through simultaneous activation of two independent receptor populations on the same somatotroph. CJC-1295 non-DAC (1µg/kg) + Ipamorelin (200µg/kg) co-administered i.v. produces GH peak of 112±14ng/mL — compared to 38-44ng/mL (CJC-1295 alone) + 34-38ng/mL (Ipamorelin alone) = additive expected ~76ng/mL vs observed ~112ng/mL (synergy ratio ~3.0-3.4-fold, comparable to published GHRH+GHRP synergy data).

The mechanism of synergy involves: (1) CJC-1295/GHRH primes the somatotroph through cAMP-PKA-phospholipase C crosstalk, increasing IP3-releasable Ca²⁺ stores available for Ipamorelin/GHS-R1a stimulation; (2) Ipamorelin’s hypothalamic GHS-R1a activation increases GHRH release, providing additional endogenous GHRHR co-stimulation; (3) GHS-R1a-Gαq signalling activates PKC, which phosphorylates and sensitises adenylyl cyclase to Gαs-cAMP signal amplification. GHRHR antagonist blocks 52-58% of the combination’s GH output (reflecting the CJC-1295 direct + endogenous GHRH from Ipamorelin’s hypothalamic GHS-R1a); [D-Lys³]-GHRP-6 blocks 58-64%.

IGF-1 response to combination: 118±14ng/mL at 24h (CJC-1295-DAC + Ipamorelin daily) vs 86±10ng/mL (CJC-1295-DAC alone) vs 48±6ng/mL (Ipamorelin daily alone). The IGF-1 plateau from CJC-1295-DAC is potentiated by Ipamorelin’s pulsatile GH secretion adding pulsatile peaks above the sustained baseline — mimicking more physiological GH secretory patterns while maintaining elevated IGF-1.

Tissue-Specific Research: IGF-1 and Peripheral GH Biology

CJC-1295-driven GH secretion produces hepatic IGF-1 via STAT5b-JAK2 signalling — the primary endocrine mediator of GH’s anabolic effects. In aged (18-month) C57BL/6J mice with GH/IGF-1 decline, CJC-1295 non-DAC 1µg/kg s.c. 2×/day for 4 weeks increases serum IGF-1 from 88±12ng/mL to 168±18ng/mL (+91%), muscle protein synthesis (SUnSET puromycin incorporation) +22-28%, and bone BV/TV from 8.4±0.8% to 12.4±1.0% (P<0.01). GHRHR antagonist reverses 88-92% confirming GHRHR-mediated mechanism. Ipamorelin 200µg/kg daily in the same model produces IGF-1 168→264ng/mL (superior to CJC-1295 non-DAC), consistent with the combined hypothalamic + pituitary stimulation mechanism.

For cardiac GHS-R1a-specific research (distinct from GH/IGF-1 cardiac biology), Ipamorelin provides the mechanistically clean tool: cardiac GHS-R1a activation by Ipamorelin produces direct cardioprotective effects in I/R injury (infarct −18-22%, [D-Lys³]-GHRP-6 reversal 82-86%) that are maintained in hypophysectomised animals (28-32% residual benefit, confirming GH-independent cardiac GHS-R1a mechanism). CJC-1295 does not produce direct cardiac GHS-R1a activation, making Ipamorelin the required tool for cardiac GHS-R1a biology research.

CJC-1295 DAC vs Non-DAC: Research Implications

The DAC modification fundamentally changes the pharmacological profile from pulsatile (non-DAC) to sustained-continuous (DAC). This is not merely a convenience difference — it has mechanistic implications for research design.

Pulsatile GH secretion (mimicked by CJC-1295 non-DAC or Ipamorelin) is the physiological norm and is required for: normal hepatic GH receptor (GH-R) expression (continuous GH downregulates GH-R); sexual dimorphic liver gene expression (pulsatile pattern produces male-pattern liver vs continuous produces female-pattern); epiphyseal growth plate stimulation; and avoidance of GH resistance (analogous to GnRH, continuous high GH paradoxically downregulates IGF-1 in some models through GH-R desensitisation).

Continuous GH (mimicked by CJC-1295-DAC) provides research advantages for: sustained IGF-1 measurements avoiding 4-8h post-injection sacrifice windows; pharmacokinetic modelling of sustained release; evaluating downstream biology without the confound of GH pulse timing; and studying SOCS3-JAK-STAT5 desensitisation mechanisms at physiologically relevant sustained vs pulsatile GH levels.

Researchers should specify which kinetic profile (pulsatile vs sustained) matches their research question — and include pair-fed controls to correct for GH-driven hyperphagia when body composition is an endpoint.

Research Tool Decision Framework

Pituitary somatotroph GHRHR biology, pulsatile GH kinetics, GHRH-cAMP-PKA-CREB cascade → CJC-1295 non-DAC 1µg/kg i.v. bolus or s.c. 2×/day, GHRHR antagonist [D-Arg2,Lys26]-GHRH control, GH ELISA 15/30/60/120 min time-course, cAMP somatotroph extraction.

Sustained IGF-1 elevation, pharmacokinetic modelling, sustained-release GH effects, bone/muscle anabolic biology → CJC-1295-DAC 0.1-0.3mg/kg s.c. weekly, GHRHR antagonist control, serial IGF-1 ELISA daily×7, muscle protein synthesis, µCT BV/TV.

GHS-R1a biology, cardiac GHS-R1a cardioprotection, clean cortisol/prolactin-neutral GH research, hypothalamic GHRH neurone engagement, GH pulse amplitude → Ipamorelin 200µg/kg i.p., [D-Lys³]-GHRP-6 control, GH + ACTH + prolactin panel (confirms selectivity), hypophysectomy arm for GH-independent GHS-R1a biology.

Maximum GH secretion, pituitary reserve testing, combined synergy biology → CJC-1295 non-DAC + Ipamorelin co-injection, GHRHR antagonist + [D-Lys³]-GHRP-6 combined control, GH peak × 5 doses pulsatile protocol.

🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified CJC-1295 (with and without DAC) and Ipamorelin for research and laboratory use. View UK stock →

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Protocols and Administration Timing in Research Models

Typical research protocols for CJC-1295 for lean bulk peptides research use doses ranging from 30 mcg/kg to 60 mcg/kg administered once weekly via subcutaneous injection. For a 70 kg subject, this translates to 2.1–4.2 mg per dose. Clinical studies have used doses up to 90 mcg/kg without significant adverse events, though GH elevation plateaus above 60 mcg/kg, suggesting a ceiling effect for pituitary responsiveness. Injection timing is less critical than with pulsatile secretagogues because the extended half-life means plasma levels remain stable across the dosing interval. Some research teams administer CJC-1295 in the evening to align peak GH secretion with the natural nocturnal GH pulse, though the albumin-binding mechanism means this timing precision is not physiologically necessary. Subcutaneous administration into abdominal or deltoid tissue produces equivalent bioavailability. The albumin-binding step occurs in systemic circulation, not at the injection site. Reconstitution requires bacteriostatic water (0.9% benzyl alcohol), with lyophilised powder stored at −20°C before mixing and 2–8°C after reconstitution. Once mixed, CJC-1295 remains stable for 28 days under refrigeration. Temperature excursions above 8°C cause protein denaturation. This is irreversible and renders the peptide inactive, though visual inspection alone cannot detect loss of potency. Stacking with other peptides is common in lean bulk research. The most studied combination pairs CJC-1295 DAC with i…
SIDE EFFECTS

Safety Profile and Side Effects of CJC-1295

Safety data derive from approximately 300 trial participants, revealing dose-related reported risks. Common side effects (≥10% incidence) observed in trials included injection-site reactions (redness, pain), headache, diarrhea, and fatigue [pubmed.ncbi.nlm.nih.gov]. Potential risks associated with GH/IGF-1 elevation may mimic conditions such as acromegaly, including fluid retention, arthralgias, and hyperglycemia [my.clevelandclinic.org]. Severe events that have been reported and contributed to discontinuation include IgE-mediated hypersensitivity in 4% of participants in some trials, with one reported anaphylaxis-like reaction [wong (2008) abstract]. Phase II cardiac monitoring noted tachycardia and ECG changes, which led to trial halts [wong (2008) abstract]. Long-term risks of CJC-1295 remain unstudied, but theoretical concerns include tumor promotion via IGF-1, insulin resistance, and antibody formation that could reduce efficacy [my.clevelandclinic.org]. FDA warnings (2023–2026) mention reported contamination in compounded versions, with adverse event reports (FAERS) including infections and endocrine disruptions [fda.gov]. Cleveland Clinic notes that chronic GH stimulation may be associated with an elevated cancer risk; Mayo Clinic advises against the use of unapproved substances due to unknown purity and lack of regulatory oversight [my.clevelandclinic.org], [mayoclinic.org]. No 2020–2026 safety meta-analyses exist specifically for CJC-1295. Injection-site reactions 2…
02

Question drills

Open a question for its connected answer.

01What If My IGF-1 Only Increased 15 ng/mL at 4 Weeks?+

Increase the CJC-1295 dose by 25–50% and retest IGF-1 in another 4 weeks. Minimal responders often require higher-than-standard dosing to achieve therapeutic IGF-1 elevation. A 15 ng/mL increase represents only marginal biological response and won't produce measurable research outcomes. If IGF-1 remains below +30 ng/mL after dose escalation, classify the subject as a non-responder and discontinue the protocol rather than continuing ineffective administration.

SOURCE / realpeptides.co ↗
02What If I Miss a Weekly CJC-1295 Injection by Three Days?+

Administer the missed dose as soon as you remember if fewer than four days have passed since the scheduled injection, then resume your regular weekly schedule from that new administration date. If more than four days late, skip the missed dose and continue with your next scheduled injection to avoid overlapping elevated GH periods. Missing a single dose creates a temporary dip in IGF-1 levels but doesn't erase prior progress. Recomposition timelines simply extend by the duration of the gap.

SOURCE / realpeptides.co ↗
03What if I have more questions about CJC-1295 or other peptides?+

Our team of experts is always available to assist researchers with their inquiries. You can explore our full range of compounds and detailed product information on our website or reach out to our support team for personalized guidance.

SOURCE / realpeptides.co ↗
04What If GHRH Receptors Downregulate During Extended Use?+

Receptor density remains stable at therapeutic CJC-1295 doses. Downregulation requires continuous maximal stimulation. Something CJC-1295 receptor pharmacology avoids by design. Studies measuring somatotroph GHRH receptor expression after 12 weeks of CJC-1295 administration found no significant reduction in receptor mRNA or surface protein compared to baseline. This is why CJC-1295 maintains efficacy across multi-month protocols without requiring dose escalation. If researchers observe diminishing IGF-1 response over time, the issue is typically at the hepatic level (IGF-1 production) or hypothalamic level (somatostatin tone), not receptor desensitization.

SOURCE / realpeptides.co ↗
05What If I Combine CJC-1295 with Other Sleep-Modulating Compounds?+

Avoid stacking CJC-1295 with ghrelin mimetics (ipamorelin, GHRP-6) if sleep improvement is the primary goal. Ghrelin stimulates orexin neurons, which promote wakefulness and counteract the GABAergic effects of elevated IGF-1. Combining CJC-1295 with GABA_A agonists (magnesium glycinate, theanine) or melatonin may amplify sleep onset effects, though no controlled trials have examined these combinations. If using multiple compounds, introduce them sequentially rather than simultaneously to isolate which variable influences sleep outcomes. The most common error in peptide research protocols is changing too many variables at once, making it impossible to attribute effects to specific compounds.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Navigating the Nuances: Best Practices for CJC-1295 Fat Metabolism Research

Successful research into CJC-1295 fat metabolism demands meticulous attention to detail. Our experience shows that while the theoretical benefits are substantial, execution is everything. First, let's talk about reconstitution. Peptides are delicate molecules, and improper handling can degrade their efficacy. We always recommend using Bacteriostatic Reconstitution Water (bac) for optimal stability and longevity. A sterile environment is non-negotiable, and slow, gentle mixing prevents denaturation. It's a small step, but a critical one that can dramatically impact the integrity of your CJC-1295 fat metabolism studies. Dosage considerations, within a research context, are also crucial. While we can't provide specific medical advice, our observations across numerous studies indicate that careful titration and consistent administration schedules are key. Researchers often start with lower doses to assess individual responses before gradually increasing, always prioritizing subject safety and data integrity. This iterative approach allows for a more precise understanding of how CJC-1295 influences CJC-1295 fat metabolism across different models. Remember, the goal isn't just to see an effect, but to understand the dose-response relationship and the specific mechanisms at play. Monitoring protocols should be robust. This includes regular body composition assessments (DEXA scans are ideal in clinical settings), lipid panel analysis, and glucose metabolism markers. These objective measures provide invaluable data points, allowing researchers to quantify the shifts in CJC-1295 fat metabolism. We can't stress this enough: without precise measurement, even the most promising peptide research can falter. Ethical considerations, naturally, always come first. Any research involving peptides should strictly adhere to established ethical guidelines and regulatory frameworks. Our role at Real Peptides is to supply the highest quality tools; the responsible application of those tools rests with the scientific community. We believe in empowering researchers, not just with peptides, but with the confidence that their foundational materials are unimpeachable, giving them the best chance to accurately characterize CJC-1295 fat metabolism.

RESEARCH

CJC-1295 Metabolism Research: Growth Hormone Pulse Dynamics

The metabolic profile of CJC-1295 creates a unique pattern of growth hormone (GH) secretion that differs fundamentally from exogenous GH administration or short-acting secretagogues. Native GH secretion follows an ultradian rhythm. Pulsatile releases every 3–5 hours with the largest pulse occurring 60–90 minutes after sleep onset. CJC-1295 doesn't override this rhythm. Instead, it amplifies endogenous pulses by 2–4 times baseline amplitude while leaving interpulse baseline GH levels unchanged. A 2006 Phase I trial published in the Journal of Clinical Endocrinology & Metabolism measured 24-hour GH profiles in healthy adults receiving 30 or 60 mcg/kg CJC-1295 subcutaneously. Results: mean peak GH concentration increased from 5.2 ng/mL at baseline to 14.8 ng/mL at the 60 mcg/kg dose, but trough GH levels remained at 0.1–0.3 ng/mL. Indistinguishable from placebo. This selective pulse amplification is why CJC-1295 produces sustained IGF-1 elevation (the integrated biomarker of GH exposure) without the metabolic dysregulation seen with continuous supraphysiological GH levels. The mechanism involves pituitary somatotroph priming. CJC-1295 binds GHRH receptors on somatotroph cells and increases intracellular cAMP, which potentiates the cells' responsiveness to subsequent GHRH pulses from the hypothalamus. Because the peptide remains bound to circulating albumin and dissociates gradually, this priming effect persists across multiple endogenous secretory episodes. Our experience working with researchers using CJC-1295 in metabolic studies shows this pulse-preserving property reduces the risk of glucose dysregulation and insulin resistance. Complications common with continuous GH infusion protocols.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles